Clinical Phase I Investigation of Intravenous Oil Attached Mycobacterial Components as Immunotherapeutic Agents
Nonspecific immunostimulation with mycobacterial agents, especially BCG, have been widely utilized (1) in an effort to increase host resistance to malignancy. Crude viable and/or killed mycobacterial agents are heterogenous preparations (2, 3), which have a significant incidence of morbidity. From an immunotherapeutic viewpoint, BCG has been shown (4, 5), in high doses, to cause splenic suppressor cells in mice, and has been implicated in causing tumor enhancement (6). Because of these problems, major interest has centored on the purification and use of microbial components.
KeywordsMycobacterium Smegmatis Cancer Immunol Tumor Enhancement Immunotherapeutic Agent Cell Wall Skeleton
Unable to display preview. Download preview PDF.
- 4.Florentin, I., R. Huchet, M. Bruley-Rosset, O. Halle-Pannenko and G. Mathe. 1976. Studies on the mechanism of action of BCG. Cancer Immunol. Immunother. 1: 31–39.Google Scholar
- 5.Gefford, M., and S. Orbach-Arbuoys. 1976. Enhancement of T suppressor activity in mice by high doses of BCG. Cancer Immunol. Immunother. 1: 41–45.Google Scholar
- 6.Bornstein, R. R., M. J. Mastrangelo, N. Sulit, D. Chee, J. W. Yarboro, L. Prehn, and R. J. Prehn. 1973. Immunotherapy of melanoma with intralesional BCG. Nat. Cancer Inst. Monog. 39: 213–215.Google Scholar
- 7.McLaughlin, C. A., S. M. Strain, W. D. Bickel, M. B. Goren, K. Azuma, K. Milner, J. L. Cantrell, and E. Ribi. 1978. Regression of line 10 hepatocellular carcinomas following treatment with water-soluble microbial extracts combined with trehalose or arabinose mycolates. Cancer Immunol. Immunother. 4: 61–68.Google Scholar
- 8.Milas, L., N. Hunter, and H. R. Withers. 1975. Combination of local irradiation with systemic applications of anaerobic corynebacterium in therapy of a murine fibrosarcoma. Cancer Res. 35: 1274–1277.Google Scholar
- 11.Halpern, B. (ed.). 1975. Corynebacterium parvum: Applications in experimental and clinical oncology. Plenum Press, New York.Google Scholar
- 12.Azuma, I., E. Ribi, T. J. Meyer, and B. Zbar. 1974. Biologically active components of mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J. Nat. Cancer Inst. 52: 95–101.Google Scholar
- 16.Vosika, G. J., Schmidtke, A. Goldman, E. Ribi, R. Parker, and G. R. Gray. 1978. Local and systemic immunotherapy of human cancer with mycobacterial cell wall skeleton and trehalose dimycolate (P3), p. 33–51. In E. M. Hersh, M. A. Chirigos and M. J. Mastrangelo (eds.), Augmenting agents in cancer therapy. Raven Press, New York, N. Y.Google Scholar